EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY-NC 4.0

A Longitudinal Post-authorization Safety Study of Golimumab in Treatment of Ulcerative Colitis: A Cohort Study in Denmark and Sweden, 2013–2021

Annette Kjær Ersbøll, Zhiping Huang, Deanna D Hill, Simone Møller Hede, Vibeke Andersen, Kristian Bolin, Marie Skov Kristensen, Suzan Esslinger, Frida Richter Hansen, Erik Hertervig, Lila Kallio, Thora Majlund Kjærulff und 8 weitere

Drug Safety · 2025

DOI: 10.1007/s40264-025-01519-8 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Drug Safety, 2025. Verfasst von Annette Kjær Ersbøll und 19 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark. ake@sdu.dk. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Antibodies, Monoclonal. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck, University of Southern Denmark.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: When golimumab (GLM) was approved for the treatment of moderate to severe ulcerative colitis (UC) in 2013, a post-authorization safety study was conducted. OBJECTIVE: Our objective was to examine whether exposure to GLM was associated with an increased incidence of all-cause total colectomy, colorectal cancer, and hepatosplenic T-cell lymphoma in Denmark and Sweden. METHODS: We conducted a new-user, active comparator cohort study of patients with UC in 2013-2021. Exposure to GLM, other anti-tumor necrosis factor (TNF) agents (infliximab and adalimumab) and thiopurines was a time-varying variable. Therapies were based on prescription redemptions and hospital-based administration of medications from national prescription and hospital registers. The association between exposure to study therapies and outcomes was evaluated using Poisson regression of incidence rates (IRs), presented as IR ratios (IRRs) and 95% confidence intervals (CIs). RESULTS: A total of 5177 and 7469 patients were included in Denmark and Sweden, respectively. The IR of all-cause total colectomy per 1000 person-years was higher in Denmark (IR 42.6; 95% CI 38.9-46.2) than in Sweden (IR 16.1; 95% CI 14.2-18.0). No significant difference was observed in all-cause total colectomy between GLM and other anti-TNF agents (Denmark: adjusted IRR [aIRR] 1.28; 95% CI 0.98-1.66; Sweden: aIRR 1.17; 95% CI 0.72-1.90). A significant difference was observed between GLM and thiopurines (Denmark: aIRR 13.62; 95% CI 8.73-21.26; Sweden: aIRR 4.52; 2.75-7.41). Privacy regulations prevented analysis of a few colorectal cancer events. No hepatosplenic T-cell lymphoma events were identified. CONCLUSION: The IR of all-cause total colectomy with GLM was similar to that with other anti-TNF agents but was much higher than with thiopurines, probably related to confounding by indication.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeAntibodies, MonoclonalHumansDenmarkSwedenFemaleMaleMiddle AgedAdultCohort StudiesLongitudinal StudiesColectomyAgedTumor Necrosis Factor InhibitorsIncidence

Substanzen

golimumabAntibodies, MonoclonalTumor Necrosis Factor Inhibitors

Autor:innen und Institutionen

  • National Institute of Public Health, University of Southern Denmark, Copenhagen, Denmark. ake@sdu.dk.
  • Merck Sharp & Dohme, LLC, Rahway, NJ, USA.
  • MedEngine DK ApS, Copenhagen, Denmark.
  • Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark.
  • Institute of Regional Health Research, University of Southern Denmark, Odense, Denmark.
  • Department of Internal Medicine, Molecular Diagnostics and Clinical Research Unit, University Hospital of Southern Denmark, Åbenrå, Denmark.

Förderung

  • Merck
  • University of Southern Denmark

Zitieren

APA

Ersbøll, A. K., Huang, Z., Hill, D. D., Hede, S. M., Andersen, V., Bolin, K., Kristensen, M. S., Esslinger, S., Hansen, F. R., Hertervig, E., Kallio, L., Kjærulff, T. M., Kloster, S., Krumme, A., Lewis, J. D., Mehkri, L., Qvist, N., Thygesen, L. C., Weinstein, C., & Green, A. (2025). A Longitudinal Post-authorization Safety Study of Golimumab in Treatment of Ulcerative Colitis: A Cohort Study in Denmark and Sweden, 2013–2021. Drug Safety. https://doi.org/10.1007/s40264-025-01519-8

Vancouver

Ersbøll AK, Huang Z, Hill DD, Hede SM, Andersen V, Bolin K, et al. A Longitudinal Post-authorization Safety Study of Golimumab in Treatment of Ulcerative Colitis: A Cohort Study in Denmark and Sweden, 2013–2021. Drug Safety. 2025. doi:10.1007/s40264-025-01519-8

BibTeX
@article{Ersbll2025,
  author = {Ersbøll, Annette Kjær and Huang, Zhiping and Hill, Deanna D and Hede, Simone Møller and Andersen, Vibeke and Bolin, Kristian and Kristensen, Marie Skov and Esslinger, Suzan and Hansen, Frida Richter and Hertervig, Erik and Kallio, Lila and Kjærulff, Thora Majlund and Kloster, Stine and Krumme, Alexis and Lewis, James D and Mehkri, Laila and Qvist, Niels and Thygesen, Lau Caspar and Weinstein, Cindy and Green, Anders},
  title = {A Longitudinal Post-authorization Safety Study of Golimumab in Treatment of Ulcerative Colitis: A Cohort Study in Denmark and Sweden, 2013–2021},
  journal = {Drug Safety},
  year = {2025},
  doi = {10.1007/s40264-025-01519-8}
}
Kostenlos starten →